Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent…
| Price | $0.31 |
|---|---|
| Market cap | $12.79M |
| Sector | Healthcare |
| Industry | Medical - Pharmaceuticals |
| Exchange | NASDAQ |
| 52-week range | 0.238-2.6 |
| Beta | 3.98 |
Explore SCNX's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.